These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29044643)

  • 1. Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium difficile-Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation.
    Reveles KR; Backo JL; Corvino FA; Zivkovic M; Broderick KC
    Pharmacotherapy; 2017 Dec; 37(12):1489-1497. PubMed ID: 29044643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
    Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
    Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
    Watt M; Dinh A; Le Monnier A; Tilleul P
    J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.
    Gallagher JC; Reilly JP; Navalkele B; Downham G; Haynes K; Trivedi M
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7007-10. PubMed ID: 26324268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
    Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States.
    Stranges PM; Hutton DW; Collins CD
    Value Health; 2013; 16(2):297-304. PubMed ID: 23538181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.
    Burton HE; Mitchell SA; Watt M
    Pharmacoeconomics; 2017 Nov; 35(11):1123-1140. PubMed ID: 28875314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
    Watt M; McCrea C; Johal S; Posnett J; Nazir J
    Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
    Nelson RL; Suda KJ; Evans CT
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.
    Cornely OA; Watt M; McCrea C; Goldenberg SD; De Nigris E
    J Antimicrob Chemother; 2018 Sep; 73(9):2529-2539. PubMed ID: 29800295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
    Okumura H; Ueyama M; Shoji S; English M
    J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price.
    Sclar DA; Robison LM; Oganov AM; Schmidt JM; Bowen KA; Castillo LV
    Clin Drug Investig; 2012 Aug; 32(8):e17-24. PubMed ID: 22708825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies.
    Chen LF; Anderson DJ
    Future Microbiol; 2012 Jun; 7(6):677-83. PubMed ID: 22702523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of outcomes with vancomycin or metronidazole for mild-to-moderate Clostridium difficile associated diarrhea among solid organ transplant recipients: A retrospective cohort study.
    Nguyen CT; Li J; Anders S; Garcia-Diaz J; Staffeld-Coit C; Hand J
    Transpl Infect Dis; 2018 Jun; 20(3):e12867. PubMed ID: 29512244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting.
    Lam SW; Neuner EA; Fraser TG; Delgado D; Chalfin DB
    Infect Control Hosp Epidemiol; 2018 Aug; 39(8):924-930. PubMed ID: 29961435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain.
    Rubio-Terrés C; Aguado JM; Almirante B; Cobo J; Grau S; Salavert M; González Antona Sánchez E; López Gutiérrez C; Rubio-Rodríguez D
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1105-1111. PubMed ID: 30989419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
    Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
    Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin.
    Cornely OA; Miller MA; Fantin B; Mullane K; Kean Y; Gorbach S
    J Clin Oncol; 2013 Jul; 31(19):2493-9. PubMed ID: 23715579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin.
    Morrow T
    Manag Care; 2011 Jul; 20(7):49-50. PubMed ID: 21848202
    [No Abstract]   [Full Text] [Related]  

  • 20. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
    Rao K; Zhao Q; Bell J; Krishnan J; Henig O; Daniel J; Sawaya K; Albin O; Mills JP; Petty LA; Gregg K; Kaul D; Malani AN; Pogue J; Kaye KS
    Clin Infect Dis; 2024 Feb; 78(2):277-282. PubMed ID: 37797310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.